The Role of Subclinical Hypothyroidism in the Pathogenesis and Course of Chronic Heart Failure
https://doi.org/10.31550/1727-2378-2024-23-4-15-19
Abstract
Aim. To summarize the currently available information about the mechanism of development of chronic heart failure against the background of subclinical hypothyroidism.
Key points. The review article is devoted to the influence of subclinical hypothyroidism on the course of cardiovascular pathologies, in particular chronic heart failure. The mechanisms of molecular cellular disorders in this disease are presented. A special role is assigned to the protein of the myocardium phospholamban. The importance of subclinical hypothyroidism as a risk factor and as an independent nosology within the framework of comorbid conditions associated with pathology of the vascular bed is described. The pathogenesis of left ventricular dysfunction in a patient and, as a consequence, chronic heart failure in patients with subclinical hypothyroidism is shown. Data from studies of patients with cardiovascular diseases against the background of elevated thyroid stimulating hormones levels are presented. The topic of the relationship between heart rhythm disturbances and thyroid hormone deficiency is also touched upon.
Conclusion. The role of subclinical hypothyroidism in the pathogenesis of chronic heart failure has been established, not only as a risk factor for its development, but also as an independent nosological form, the presence of which naturally leads to adverse cardiovascular events.
About the Authors
A. S. Mikulsky
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Mikulsky, A.S.
6 Academician Lebedev Str., Saint Petersburg, 194044
G. G. Kutelev
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Kutelev, G.G.
6 Academician Lebedev Str., Saint Petersburg, 194044
K. S. Shulenin
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Shulenin, K.S.
6 Academician Lebedev Str., Saint Petersburg, 194044
M. V. Salnikov
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Salnikov, M.V.
6 Academician Lebedev Str., Saint Petersburg, 194044
References
1. Fadeyev V., Zakharova S., Artemova A., Vanushko V. et al. The epidemiology of the thyroid disorders in the elderly: results of screening in nursing homes in Moscow. Turkish J. Endocrinol. Metab. 2014;8(suppl.1):142. (Abstracts of the 30th annual meeting of the European Thyroid Association).
2. Ettleson M.D. Cardiovascular outcomes in subclinical thyroid disease: an update. Curr. Opin. Endocrinol. Diabetes Obes. 2023;30(5):218–24. DOI: 10.1097/MED.0000000000000818
3. Wilson S., Parle J.V., Roberts L.M., Roalfe A.K. et al. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J. Clin. Endocrinol. Metab. 2006;91(12):4809–16. DOI: 10.1210/jc.2006-1557
4. Ahmadi N., Ahmadi F., Sadiqi M., Ziemnicka K. et al. Thyroid gland dysfunction and its effect on the cardiovascular system: a comprehensive review of the literature. Endokrynol. Pol. 2020;71(5):466–78. DOI: 10.5603/EP.a2020.0052
5. Hak A.E., Pols A., Visser T.J., Drexhage H.A. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 2000;132(4):270–8. DOI: 10.7326/0003-4819-132-4-200002150-00004
6. Müller P., Leow M.K., Dietrich J.W. Minor perturbations of thyroid homeostasis and major cardiovascular endpoints — physiological mechanisms and clinical evidence. Front. Cardiovasc. Med. 2022;9:942971. DOI: 10.3389/fcvm.2022.942971
7. Casis O., Echeazarra L., Sáenz-Díez B., Gallego M. Deciphering the roles of triiodothyronine (T3) and thyroid-stimulating hormone (TSH) on cardiac electrical remodeling in clinical and experimental hypothyroidism. J. Physiol. Biochem. 2024;80(1):1–9. DOI: 10.1007/s13105-023-01000-z
8. Klein I., Ojamaa K. Тhyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001;344(7):501–9. DOI: 10.1056/nejm200102153440707
9. Biondi B., Klein I. Hypothyroidism as a risk factor for hypothyroidism. Endocrine. 2004;24(1):1–13. DOI: 10.1385/ENDO:24:1:001
10. Virtanen V., Saha H., Groundstroem K., Salmi J. et al. Thyroid hormone substitution therapy rapidly enhances left-ventricular diastolic function in hypothyroid patients. Cardiology. 2001;96(2):59–64. DOI: 10.1159/000047390
11. Stamatouli A., Bedoya P., Yavuz S. Hypothyroidism: cardiovascular endpoints of thyroid hormone replacement. Front. Endocrinol. (Lausanne). 2020;10:888. DOI: 10.3389/fendo.2019.00888
12. Агеев Ф.Т., Бланкова З.Н., Середенина Е.М., Рябцева О.Ю. и др. Эффективность и безопасность заместительной гормонотерапии левотироксином у больных с субклиническим гипотиреозом и сердечной недостаточностью. Кардиология. 2011;51(5): 70–7.
13. Бланкова З.Н., Середенина Е.М., Агеев Ф.Т. Субклинический гипотиреоз как фактор риска сердечно-сосудистых заболеваний и СН. Сердце. 2009;8(2):68–72.
14. Nagasaki T., Inaba M., Yamada S., Kumeda Y. et al. Changes in brachial-ankle pulse wave velocity in subclinical hypothyroidism during normalization of thyroid function. Biomed. Pharmacother. 2007;61(8):482–7. DOI: 10.1016/j.biopha.2007.04.004
15. Owen P.J., Rajiv C., Vinereanu D., Mathew T. et al. Subclinical hypothyroidism, arterial stiffness and myocardial reserve. J. Clin. Endocrinol. Metab. 2006;91(6):2126–32. DOI: 10.1210/jc.20052108
16. Dagre A.G., Lekakis J.P., Papaionnou T.G., Papamichael C.M. et al. Аrterial stiffness is increased in subjects with hypothyroidism. Int. J. Cardiol. 2005;103(1):1–6. DOI: 10.1016/j.ijcard.2005.05.068
17. Palmieri E.A., Fazio S., Lombardi G., Biondi B. Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat. Endocrinol. 2004;3(4):233–44. DOI: 10.2165/00024677-200403040-00005
18. Ripoli A., Pingitore A., Favilli B., Bottoni A. et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J. Am. Coll. Cardiol. 2005;45(3):439–45. DOI: 10.1016/j.jacc.2005.10.044
19. Iqbal A., Schirmer H., Lunde P., Figenschau Y. et al. Thyroid stimulating hormone and left ventricular function. Clin. Endocrinol. Metab. 2007;92(9):3504–10. DOI: 10.1210/jc.2017-0727
20. Dillmann W.H. Cellular action of thyroid hormone on the heart. Thyroid. 2002;12(6):447–52. DOI: 10.1089/105072502760143809
21. Vitale G., Galderisi M., Lupoli G.A., Celentano A. et al. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J. Clin. Endocrinol. Metab. 2002;87(9):4350–5. DOI: 10.1210/jc.2002-011764
22. Yazici M., Gorgulu S., Sertbas Y., Erbilen E. et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. Int. J. Cardiol. 2004;95(2–3):135–43. DOI: 10.1016/j.ijcard.2004.05.015
23. Arinc H., Gunduz H., Tamer A., Seyfeli E. et al. Tissue Doppler echocardiography in evaluation of cardiac effects of subclinical hypothyroidism. Int. J. Cardiovasc. Imaging. 2006;22:177–86. DOI: 10.1007/s10554-005-9030-2
24. Monzani F., Di Bello V., Caraccio N., Bertini A. et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2001;86(3):1110–15. DOI: 10.1210/jcem.86.3.7291
25. Virtanen V.K., Saha H.H., Groundstroem K.W., Salmi J. et al. Thyroid hormone substitution therapy rapidly enhances leftventricular diastolic function in hypothyroid patients. Cardiology. 2001;96(2):59–64. DOI: 10.1159/000047390
26. Wang W., Zhang X., Gao J., Meng X. et al. Effects of levothyroxine in subclinical hypothyroidism and heart failure with reduced ejection fraction: an open-label randomized trial. Cell Rep. Med. 2024;5(4):101473. DOI: 10.1016/j.xcrm.2024.101473
27. Lacoviello M., Guida P., Guastamacchia E., Triggiani V. et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des. 2008;14(26):2686–92. DOI: 10.2174/138161208786264142
28. Metra M., Tomasoni D., Adamo M., Bayes-Genis A. et al. Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2023;25(6):776–91. DOI: 10.1002/ejhf.2874
29. Lee S.C., Stevens T.L., Sandberg S.M., Heublein D.M. et al. The potential of brain natriuretic peptide a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J. Card. Fail. 2002;8(3):149–54. DOI: 10.1054/jcaf.2022.125368
30. Christ-Crain M., Morgenthaler N.G., Meier C., Müller C. et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. Swiss Med. Wkly. 2005;135: 549–54. DOI: 10.4414/smw.2015.11119
31. Bayes-Genis A., Docherty K.F., Petrie M.C., Januzzi J.L. et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur. J. Heart Fail. 2023;25(11):1891–8. DOI: 10.1002/ejhf.3036
32. Echouffo-Tcheugui J.B., Zhang S., Daya N., McEvoy J.W. et al. NT-proBNP and all-cause and cardiovascular mortality in US adults: a prospective cohort study. J. Am. Heart Assoc. 2023;12(11):e029110. DOI: 10.1161/JAHA.122.029110
33. Ibrahim N.E., Januzzi J.L. Jr. NT-proBNP concentrations in the community: elevation, deficiency, and everything in between. JACC Heart Fail. 2024;12(1):64–6. DOI: 10.1016/j.jchf.2023.08.014
34. Ozmen B., Ozmen D., Parildar Z., Mutaf I. et al. Serum N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Endocr. Res. 2007;32(1–2):1–8. DOI: 10.1080/07435800701670047
35. Schultz M., Faber J., Kistorp C., Jarløv A. et al. N-terminal-pro-B-type natiuretic peptide (NT-pro-BNP) in different thyroid function states. Clin. Endocrinol. (Oxf). 2004;60(1):54–9. DOI: 10.1111/j.1365-2265.2004.01941.x
36. Manuchehri A.M., Jayagopal V., Kilpatrick E.S., Atkin S.L. The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Ann. Clin. Biochem. 2006;43(3):184–8. DOI: 10.1258/000456306776865089
37. Koglin J., Pehlivanli S., Shwaiblmair M., Vogeser M. et al. Role of brain natriuretic peptide in risk stratification of patient with congestive heart failure. J. Am. Coll. Cardiol. 2001;38(7):1934–41. DOI: 10.1016/s0735-1097(01)01672-2
Review
For citations:
Mikulsky A.S., Kutelev G.G., Shulenin K.S., Salnikov M.V. The Role of Subclinical Hypothyroidism in the Pathogenesis and Course of Chronic Heart Failure. Title. 2024;23(4):15-19. (In Russ.) https://doi.org/10.31550/1727-2378-2024-23-4-15-19
Views:
10
Email this article 